Turn Therapeutics (TTRX) Registration Filing summary

Company overview and business model

• Focuses on pharmaceutical and medical device development using a proprietary PermaFusion platform for stable suspension of APIs in oil-based carriers, targeting enhanced drug performance and reduced adverse events.

• Lead programs address moderate to severe eczema and onychomycosis, with additional applications in wound care and thermostable intranasal vaccines.

• Business model combines internal drug development with licensing of medical device technologies to commercial partners, aiming for capital efficiency and optionality.

• Operates with a lean internal team, leveraging contractors and vendors to minimize cash burn and maximize capital for clinical development.

• Holds multiple FDA clearances for medical devices and is pursuing new drug approvals for key dermatology indications.

Financial performance and metrics

• Reported net losses of $1.57M for the six months ended June 30, 2025, and $1.77M for the year ended December 31, 2024; accumulated deficit of $20.76M as of June 30, 2025.

• Cash and cash equivalents were $3.19M as of June 30, 2025, with total assets of $4.33M and total liabilities of $2.56M.

• No product revenue generated in 2024 or 2025; revenue recognition deferred for licensing agreements pending regulatory milestones.

• Operating expenses primarily driven by R&D and general administrative costs, with increased legal and advisory fees in 2025 related to the direct listing.

• Financial statements express substantial doubt about ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• May receive up to $85M in gross proceeds from GEM under the equity facility, to be used for working capital and general corporate purposes.

• Proceeds from the GEM Purchase Agreement are intended to fund clinical trials, R&D, and general operations, with broad discretion in allocation.

• No proceeds from the sale of shares by selling stockholders; company only receives funds from direct sales to GEM.